METASTATIC CASTRATION RESISTANT PROSTATE CANCER
Clinical trials for METASTATIC CASTRATION RESISTANT PROSTATE CANCER explained in plain language.
Never miss a new study
Get alerted when new METASTATIC CASTRATION RESISTANT PROSTATE CANCER trials appear
Sign up with your email to follow new studies for METASTATIC CASTRATION RESISTANT PROSTATE CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug combo targets Hard-to-Treat prostate cancer
Disease control OngoingThis early-stage trial tests whether two oral drugs, talazoparib and tazemetostat, can be safely combined to treat metastatic castration-resistant prostate cancer (mCRPC), a form of prostate cancer that has spread and stopped responding to hormone therapy. About 35 participants w…
Matched conditions: METASTATIC CASTRATION RESISTANT PROSTATE CANCER
Phase: PHASE1 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated May 26, 2026 03:21 UTC
-
New drug combo shows promise in slowing advanced prostate cancer
Disease control OngoingThis study tests whether adding olaparib to standard abiraterone therapy can help men with a certain type of advanced prostate cancer that no longer responds to hormone therapy. About 895 men will receive either the combination or a placebo plus abiraterone. The main goal is to s…
Matched conditions: METASTATIC CASTRATION RESISTANT PROSTATE CANCER
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated May 26, 2026 03:21 UTC
-
New radioactive drug aims to shrink prostate cancer tumors
Disease control OngoingThis phase II trial tests a new drug called FPI-2265 for men with a hard-to-treat type of advanced prostate cancer. The drug delivers a tiny dose of radiation directly to cancer cells. The main goal is to see if it can lower PSA levels, a marker of cancer activity, in 115 partici…
Matched conditions: METASTATIC CASTRATION RESISTANT PROSTATE CANCER
Phase: PHASE2 • Sponsor: Fusion Pharmaceuticals Inc. • Aim: Disease control
Last updated May 26, 2026 03:17 UTC
-
New hope for tough prostate cancer: targeted radiation after other treatments fail
Disease control OngoingThis study tests a new drug, FPI-2265, which delivers targeted radiation to prostate cancer cells. It is for men with advanced prostate cancer that has stopped responding to hormone therapy and who have already had a similar type of radiation treatment. The goal is to find the sa…
Matched conditions: METASTATIC CASTRATION RESISTANT PROSTATE CANCER
Phase: PHASE2 • Sponsor: Fusion Pharmaceuticals Inc. • Aim: Disease control
Last updated May 26, 2026 03:17 UTC
-
New drug combo aims to shrink tough prostate tumors
Disease control OngoingThis study tests a new drug combination (FPI-2265 and olaparib) in about 85 men with a type of advanced prostate cancer that has stopped responding to standard hormone therapy. The goal is to see if the treatment can shrink tumors and lower PSA levels by at least 50%. Participant…
Matched conditions: METASTATIC CASTRATION RESISTANT PROSTATE CANCER
Phase: PHASE2 • Sponsor: Fusion Pharmaceuticals Inc. • Aim: Disease control
Last updated May 26, 2026 03:16 UTC
-
Promising drug combo aims to slow advanced prostate cancer
Disease control OngoingThis study tests whether adding olaparib to standard abiraterone therapy can delay cancer growth or death in men with metastatic castration-resistant prostate cancer who have not yet had chemotherapy. About 110 participants receive either olaparib plus abiraterone or a placebo pl…
Matched conditions: METASTATIC CASTRATION RESISTANT PROSTATE CANCER
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated May 26, 2026 03:15 UTC
-
Promising prostate cancer trial pulled before it began
Disease control TerminatedThis study aimed to test a radioactive drug, 177Lu-PSMA-617, in men with advanced prostate cancer that had spread to the bone marrow and caused low blood counts. The goal was to see if the treatment was safe and how it affected the cancer. However, the study was withdrawn before …
Matched conditions: METASTATIC CASTRATION RESISTANT PROSTATE CANCER
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 26, 2026 03:15 UTC
-
New drug combo shows promise for Hard-to-Treat prostate cancer
Disease control OngoingThis study tests whether a targeted chemotherapy drug (abemaciclib) and an immunotherapy drug (atezolizumab), alone or together, can shrink or slow advanced prostate cancer that has stopped responding to hormone therapy. Nineteen adult men with metastatic castration-resistant pro…
Matched conditions: METASTATIC CASTRATION RESISTANT PROSTATE CANCER
Phase: PHASE2 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated May 26, 2026 03:14 UTC
-
New radioactive drug takes aim at hard-to-treat prostate cancer
Disease control OngoingThis early-phase trial tests an experimental drug called [Ac-225]-PSMA-62 in 142 men with a specific type of prostate cancer that shows up on a PSMA scan. The drug delivers a tiny dose of radiation directly to cancer cells. The main goals are to find the safest dose and to check …
Matched conditions: METASTATIC CASTRATION RESISTANT PROSTATE CANCER
Phase: PHASE1 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated May 26, 2026 03:11 UTC
-
Targeted drug shows promise for Hard-to-Treat prostate cancer in chinese men
Disease control OngoingThis study looks at whether the drug olaparib works better than standard treatments (enzalutamide or abiraterone) for Chinese men with advanced prostate cancer that has spread and is no longer responding to hormone therapy. All participants have a BRCA1 or BRCA2 gene mutation. Th…
Matched conditions: METASTATIC CASTRATION RESISTANT PROSTATE CANCER
Phase: PHASE4 • Sponsor: AstraZeneca • Aim: Disease control
Last updated May 26, 2026 03:10 UTC
-
New combo shows promise for tough prostate cancer
Disease control OngoingThis study tests a combination of two drugs (ONC-392 and a radioactive therapy) in men with advanced prostate cancer that has stopped responding to hormone therapy. About 148 participants will be randomly assigned to receive the combo or standard care. The goal is to see if the c…
Matched conditions: METASTATIC CASTRATION RESISTANT PROSTATE CANCER
Phase: PHASE1, PHASE2 • Sponsor: OncoC4, Inc. • Aim: Disease control
Last updated May 26, 2026 03:08 UTC
-
New hope for tough prostate cancer: xaluritamig takes on standard care
Disease control OngoingThis study compares a new drug, xaluritamig, with two standard treatments (cabazitaxel or another hormone therapy) in 707 men with metastatic castration-resistant prostate cancer who have already had chemotherapy. The main goal is to see if xaluritamig helps people live longer. P…
Matched conditions: METASTATIC CASTRATION RESISTANT PROSTATE CANCER
Phase: PHASE3 • Sponsor: Amgen • Aim: Disease control
Last updated May 26, 2026 03:08 UTC
-
Experimental cell therapy targets Hard-to-Treat prostate cancer
Disease control OngoingThis early-phase trial tests a new treatment called PSMA-UCAR T cells for men with advanced prostate cancer that no longer responds to standard therapies. The therapy uses specially engineered immune cells to target a protein (PSMA) on cancer cells. The main goal is to check safe…
Matched conditions: METASTATIC CASTRATION RESISTANT PROSTATE CANCER
Phase: PHASE1 • Sponsor: Shanghai Changzheng Hospital • Aim: Disease control
Last updated May 26, 2026 03:08 UTC
-
New hope for veterans with tough prostate cancer: immune drug shows promise
Disease control OngoingThis study tests a drug called pembrolizumab in 40 men with advanced prostate cancer that has spread and no longer responds to hormone therapy. The drug helps the body's immune system attack cancer cells, specifically in men whose tumors have certain genetic changes. The goal is …
Matched conditions: METASTATIC CASTRATION RESISTANT PROSTATE CANCER
Phase: PHASE2 • Sponsor: VA Office of Research and Development • Aim: Disease control
Last updated May 26, 2026 02:48 UTC
-
New targeted radiation therapy shows promise for Tough-to-Treat prostate cancer
Disease control OngoingThis study tests a new treatment called [Lu-177]-PNT2002 for men with advanced prostate cancer that no longer responds to hormone therapy. The treatment delivers radiation directly to cancer cells using a targeting molecule. About 455 men will participate to see if this approach …
Matched conditions: METASTATIC CASTRATION RESISTANT PROSTATE CANCER
Phase: PHASE3 • Sponsor: POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company • Aim: Disease control
Last updated May 22, 2026 13:54 UTC
-
New drug combo studied for tough prostate cancer
Disease control OngoingThis study looked at how two prostate cancer drugs (JNJ-56021927 and abiraterone acetate) interact in the body and whether combining them is safe. It involved 57 men with metastatic castration-resistant prostate cancer, a type that no longer responds to standard hormone therapy. …
Matched conditions: METASTATIC CASTRATION RESISTANT PROSTATE CANCER
Phase: PHASE1 • Sponsor: Aragon Pharmaceuticals, Inc. • Aim: Disease control
Last updated May 22, 2026 13:54 UTC
-
New drug RS-113 shows promise in slowing advanced prostate cancer
Disease control OngoingThis study tests a new drug called RS-113 in 120 men with metastatic castration-resistant prostate cancer, a type of advanced prostate cancer that has stopped responding to standard hormone therapy. The goal is to find the best dose that can slow or stop cancer growth, and to com…
Matched conditions: METASTATIC CASTRATION RESISTANT PROSTATE CANCER
Phase: PHASE2 • Sponsor: R-Pharm International, LLC • Aim: Disease control
Last updated May 22, 2026 13:51 UTC
-
New combo therapy targets tough prostate cancer
Disease control OngoingThis early-stage study tests whether adding a chemotherapy drug (carboplatin) to a targeted radiation therapy (177Lu-PSMA-617) is safe and effective for men with advanced prostate cancer that has stopped responding to hormone therapy. About 37 participants will receive the combin…
Matched conditions: METASTATIC CASTRATION RESISTANT PROSTATE CANCER
Phase: PHASE1 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated May 22, 2026 13:51 UTC
-
New radioactive drug targets Hard-to-Treat prostate cancer
Disease control OngoingThis early-stage study tests a new drug called 225Ac-pelgi for people with advanced prostate cancer that has spread and no longer responds to hormone therapy. The drug delivers a short-range radioactive payload directly to cancer cells, aiming to kill them while sparing nearby he…
Matched conditions: METASTATIC CASTRATION RESISTANT PROSTATE CANCER
Phase: PHASE1 • Sponsor: Bayer • Aim: Disease control
Last updated May 18, 2026 12:11 UTC
-
Engineered immune cells take on Hard-to-Treat prostate cancer
Disease control OngoingThis early-phase trial tests a new treatment for men with a tough-to-treat form of advanced prostate cancer. The therapy uses the patient's own immune cells, which are modified in a lab to better recognize and attack cancer cells. The main goals are to check if the treatment is s…
Matched conditions: METASTATIC CASTRATION RESISTANT PROSTATE CANCER
Phase: EARLY_PHASE1 • Sponsor: Shanghai Changzheng Hospital • Aim: Disease control
Last updated May 18, 2026 12:03 UTC
-
New drug cocktail shows promise for Hard-to-Treat cancers
Disease control OngoingThis study tests a drug called ceralasertib, either alone or combined with olaparib or durvalumab, in people with advanced solid tumors like kidney, bladder, pancreatic, endometrial, and prostate cancers. The goal is to see if these combinations can shrink tumors or slow their gr…
Matched conditions: METASTATIC CASTRATION RESISTANT PROSTATE CANCER
Phase: PHASE2 • Sponsor: Rahul Aggarwal • Aim: Disease control
Last updated May 18, 2026 11:59 UTC
-
New drug combo shows promise for Tough-to-Treat prostate cancer
Disease control OngoingThis early-phase study tested a combination of two drugs—nivolumab (an immunotherapy) and Radium-223 (a radioactive drug)—in 39 men with advanced prostate cancer that no longer responds to hormone therapy and has spread to the bones. The main goals were to check safety and see if…
Matched conditions: METASTATIC CASTRATION RESISTANT PROSTATE CANCER
Phase: PHASE1 • Sponsor: University of Utah • Aim: Disease control
Last updated May 15, 2026 11:57 UTC
-
New hope for Hard-to-Treat prostate cancer: drug combo trial underway
Disease control OngoingThis study tests a drug called enfortumab vedotin, alone or with other medicines, in men with advanced prostate cancer that no longer responds to hormone therapy. The goal is to shrink tumors or slow the disease. About 34 men who have already tried chemotherapy will take part.
Matched conditions: METASTATIC CASTRATION RESISTANT PROSTATE CANCER
Phase: PHASE2 • Sponsor: University of Utah • Aim: Disease control
Last updated May 15, 2026 11:54 UTC
-
New radiation therapy aims to control Hard-to-Treat prostate cancer
Disease control ENROLLING_BY_INVITATIONThis study tests a new treatment called 177Lu-HTK03170 for men with a type of advanced prostate cancer that has stopped responding to hormone therapy. The treatment delivers radiation directly to cancer cells using a targeting molecule. The goal is to find a safe dose and see if …
Matched conditions: METASTATIC CASTRATION RESISTANT PROSTATE CANCER
Phase: PHASE1, PHASE2 • Sponsor: British Columbia Cancer Agency • Aim: Disease control
Last updated May 12, 2026 13:42 UTC
-
New PET scan could reveal hidden prostate cancer
Diagnosis OngoingThis early-phase study tests a new PET imaging agent (89Zr-DFO-YS5) that targets a protein called CD46, found on many aggressive prostate cancer cells. About 30 men with advanced, treatment-resistant prostate cancer will receive the agent and then have PET scans to see if it can …
Matched conditions: METASTATIC CASTRATION RESISTANT PROSTATE CANCER
Phase: PHASE1 • Sponsor: Robert Flavell, MD, PhD • Aim: Diagnosis
Last updated May 26, 2026 03:20 UTC
-
New registry to monitor PSMA therapy in prostate cancer patients
Knowledge-focused OngoingThis study is a registry that collects information on 500 men with metastatic castration-resistant prostate cancer who are treated with PSMA theranostics. The goal is to track how well the treatment lowers PSA levels and to monitor any side effects. The registry does not test a n…
Matched conditions: METASTATIC CASTRATION RESISTANT PROSTATE CANCER
Sponsor: Peter MacCallum Cancer Centre, Australia • Aim: Knowledge-focused
Last updated May 26, 2026 03:09 UTC